Premium
Management of bisphosphonate‐related osteonecrosis of the jaw: a literature review
Author(s) -
Spanou A,
Lyritis GP,
Chronopoulos E,
Tournis S
Publication year - 2015
Publication title -
oral diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.953
H-Index - 87
eISSN - 1601-0825
pISSN - 1354-523X
DOI - 10.1111/odi.12333
Subject(s) - osteonecrosis of the jaw , medicine , bisphosphonate , denosumab , bisphosphonate associated osteonecrosis of the jaw , zoledronic acid , osteoporosis , multiple myeloma , teriparatide , bone density conservation agents , malignancy , bevacizumab , bone disease , surgery , oncology , bone density , chemotherapy , bone mineral
Osteonecrosis of the jaw ( ONJ ) is a serious side effect of bisphosphonate use in patients with osteoporosis, Paget's disease, hypercalcemia of malignancy, metastatic bone disease and multiple myeloma, although recently this complication has also been reported in patients under non‐bisphosphonate medication, such as denosumab and bevacizumab. The occurrence of ONJ is higher in oncology patients treated with high‐dose iv bisphosphonates than in osteoporosis patients treated with oral bisphosphonates. Although multiple hypotheses have been proposed, the exact pathogenic mechanism of ONJ still remains unclear. As treatment protocols based on randomized controlled trials ( RCT s) do not exist, we critically reviewed the existing data concerning the management of bisphosphonate‐related osteonecrosis of the jaw, including the most recent data for the use of teriparatide and hyperbaric oxygen.